Markets & Regulations

Biosimilars: Is the Market Getting Too Much Attention?

Biosimilars: Is the Market Getting Too Much Attention?

By Zachary Brennan

As anticipation swells over how the biosimilar market will shape up in the US, some contract biologic manufacturing executives don’t seem to think the size of the market is worth all of the hype yet.

Italian drugmaker commits to ADC development

Menarini forms ADC manufacturing deal with OBT

By Gareth Macdonald

Menarini has committed millions of euros to an antibody drug conjugate (ADC) clinical development and manufacturing pact with Oxford BioTerapeutics (OBT). 

India launches 'similar biologics' guidelines at BIO2012

India launches 'similar biologics' guidelines at BIO2012

By Gareth Macdonald

New 'similar biologics' guidelines will curb the rising cost of innovation, attract overseas investment and ensure patients have access to drugs according to the Indian Government team which launched them at BIO 2012.

Biopharm quiz – how much do you know about 2010?

Interactive Quiz

Biopharm quiz – how much do you know about 2010?

By Nick Taylor

Followed the news in 2010? Then test your knowledge of biopharm in 2010 against colleagues, peers and our community of readers in our exclusive map-based quiz.